CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||10mg, 50 mg & 100mg tablet|
|Indication||Chronic Lymphocytic Leukemia|
|Funding Request||As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)|
|Pre Noc Submission||No|
|NOC Date||September 30, 2016|
|Submission Date||July 10, 2017|
|Submission Deemed Complete||July 17, 2017|
|Prioritization Requested||Requested and Granted|
|Stakeholder Input Deadline ‡||July 24, 2017|
|Check-point meeting||September 7, 2017|
|pERC Meeting||November 16, 2017|
|Initial Recommendation Issued||November 30, 2017|
|Feedback Deadline ‡||December 14, 2017|
|pERC Reconsideration Meeting||February 15, 2018|
|Final Recommendation Issued||March 2, 2018|
|Notification to Implement Issued||March 19, 2018|
|Therapeutic Area||Chronic Lymphocytic Leukemia|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.